['liver cancer']
['arq197', 'placebo']

        Inclusion Criteria:

          -  Informed consent form

          -  ≥20 years old

          -  Inoperable HCC which is not eligible for locoregional therapy

          -  Diagnosed as c-Met high in tumor sample

          -  Radiographic progression is confirmed during or after systemic chemotherapy including
             sorafenib, or those who are intolerance to the chemotherapy.

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) is 0 or 1

          -  Child-Pugh Class A

          -  Having measurable target lesions which are defined by Response Evaluation Criteria in
             Solid Tumors (RECIST) version 1.1,

          -  Negative pregnancy test results

          -  Adequate organ function

          -  Life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  More than 2 prior systemic chemotherapy.

          -  Prior therapy of c-Met inhibitor (including antibody)

          -  Any systemic therapy within ≤2 weeks prior to the randomization

          -  Locoregional therapy within ≤4 weeks prior to randomization.

          -  Major surgery within ≤4 weeks prior to the randomization

          -  Concurrent cancer within ≤5 years prior to the randomization

          -  History of cardiac diseases

          -  Active clinically serious infections defined as ≥ Grade 3 according to Common Toxicity
             Criteria for Adverse Effects (CTCAE) 4.0

          -  Any psychological disorder affecting Informed Consent

          -  Diagnosis positive for anti-HIV antibody and/or anti-HTLV-1 antibody

          -  Blood or albumin transfusion within ≤14 days prior to the screening test

          -  Concurrent interferon therapy against Hepatitis B Virus (HBV)/ Hepatitis C Virus (HCV)

          -  Symptomatic brain metastases

          -  History of liver transplantation

          -  Inability to swallow oral medications

          -  Confirmed interstitial lung disease

          -  Pleural effusion and/or clinically significant ascites

          -  Pregnancy or breast-feeding

          -  Without consent to effective single or combined contraceptive methods
      